Use of landiolol hydrochloride, a new beta-blocker, in coronary computed tomography angiography.
We investigated the usefulness of landiolol hydrochloride, an ultrashort-acting beta(1)-selective agent, for coronary computed tomography angiography (CTA). Intravenous landiolol was administered to 133 patients before coronary CTA. Hemodynamic changes, adverse effects, image quality, and diagnostic accuracy for detection of coronary stenoses were evaluated. HR was significantly reduced during injection, but quickly recovered after cessation of landiolol. Neither significant changes in BP nor adverse effects were seen. The sensitivity, specificity, and positive and negative predictive values of coronary CTA for detection of significant stenoses were excellent, compared with invasive angiography. Therefore, our results show that intravenous landiolol administration gives a favorable image quality and facilitates diagnostic accuracy without causing adverse effects, indicating that landiolol is a useful premedication for coronary CTA.
Isobe
Satoshi
S
Sato
Kimihide
K
Sugiura
Kaichiro
K
Mimura
Takeo
T
Kobayashi
Mikiko
M
Meno
Chizuka
C
Kato
Makoto
M
Ishii
Hideki
H
Murohara
Toyoaki
T
D000319:Adrenergic beta-Antagonists / Q000737:chemistry; D000368:Aged; D017023:Coronary Angiography / Q000379:methods* / Q000592:standards; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000737:chemistry; D014057:Tomography, X-Ray Computed / Q000379:methods* / Q000592:standards; D014508:Urea / Q000031:analogs & derivatives* / Q000737:chemistry
D000319:Adrenergic beta-Antagonists; D009025:Morpholines; C077049:landiolol; D014508:Urea